

## Letter to the Editor

## Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics

MV Karamouzis<sup>\*,1,2</sup>, PA Konstantinopoulos<sup>2,3</sup> and AG Papavassiliou<sup>2</sup><sup>1</sup>Division of Hematology-Oncology, University of Pittsburgh, Pittsburgh, PA, USA; <sup>2</sup>Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece; <sup>3</sup>Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

British Journal of Cancer (2007) 96, 1924–1925. doi:10.1038/sj.bjc.6603807 www.bjancer.com  
Published online 22 May 2007  
© 2007 Cancer Research UK

Sir,

We have read the recent interesting minireviews by Lo and Hung (2007) and Uramoto and Mitsudomi (2007) regarding epidermal growth factor receptor (EGFR) signalling and we would like to add the following comment to strengthen some issues of this important theme. Ligand-dependent activation of the EGFR induces several signal-transduction pathways as well as trafficking events that relocate the receptors from the cell surface to intracellular endocytic compartments that provide signal specification. Accordingly, trafficking-dependent alterations in receptor compartmentalisation are crucial regulatory mechanisms for EGFR signalling (Frey *et al*, 2006; Tanos and Pendergast, 2006). In the first step, activated receptors are removed from cell membrane and are internalised into endosomes. In the second step, EGFR may recycle back to the membrane for continued signalling or is targeted for degradation (Orth and McNiven, 2007). The later step is generally appreciated as a signalling-blocking process, although there are data suggesting that internalised receptors might still interact with effector/adaptor proteins and thus activate downstream cascades (Citri and Yarden, 2006). Defective internalisation of ligand-activated EGFR leads to prolonged signalling and has been implicated in malignant

transformation (Marmor and Yarden, 2004). This might be partly also related with the 'short-lived' observed clinical effect in some cancer patients with the currently used EGFR-TKIs, as it has been suggested that EGFR-TKIs (contrary to monoclonal antibodies) cannot produce long-term EGFR suppression through receptor internalisation and degradation. Moreover, EGFR endocytosis might have important implications in the already tested as well as the future co-administration of chemotherapy and EGFR-TKIs, since it has been recently suggested that the *in vitro* application of EGFR-TKIs before chemotherapeutic agents represses EGFR degradation (Feng *et al*, 2006). Posttranslational modifications are also a prerequisite of EGFR endocytosis. Ras superfamily of GTPases regulate important biologic processes, such as intracellular trafficking. RAB5 has been found to mediate EGFR entry into the early endosome (Barbieri *et al*, 2004; Konstantinopoulos and Papavassiliou, 2007) and RAB11 facilitates EGFR recycling to the plasma membrane (Cullis *et al*, 2002). Conversely, RAB7 is required for the degradation of the ligand-activated EGFR by the lysosome (Ceresa and Bahr, 2006). Thus, modulation of RAB-GTPases could provide an exciting alternative way of EGFR inhibition (Konstantinopoulos *et al*, 2007, in press).

## REFERENCES

- Barbieri MA, Fernandez-Pol S, Hunker C, Horazdovsky BH, Stahl PD (2004) Role of rab5 in EGF receptor-mediated signal transduction. *Eur J Cell Biol* 83: 305–314
- Ceresa BP, Bahr SJ (2006) Rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. *J Biol Chem* 281: 1099–1106
- Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. *Nat Rev Mol Cell Biol* 7: 505–516
- Cullis DN, Phillip B, Baleja JD, Feig LA (2002) Rab11-FIP2, an adaptor protein connecting cellular components involved in internalization and recycling of epidermal growth factor receptors. *J Biol Chem* 277: 49158–49166
- Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, Nyati MK (2006) Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. *Oncogene* 26: 3431–3439
- Frey MR, Dise RS, Edelblum KL, Polk DB (2006) p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. *EMBO J* 25: 5683–5692

\*Correspondence: Dr MV Karamouzis; Division of Hematology-Oncology, University of Pittsburgh, Pittsburgh, PA, USA.  
E-mail: mihkaram@hotmail.com  
Published online 22 May 2007

- Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Targeting post-translational modifications and functional regulation of the RAS superfamily of small G-proteins for anticancer drug development. *Nat Rev Drug Discov* (in press)
- Konstantinopoulos PS, Papavassiliou AG (2007) The tuberous sclerosis complex. *N Engl J Med* **356**: 92–93
- Lo HW, Hung MC (2007) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. *Br J Cancer* **94**: 184–188
- Marmor MD, Yarden Y (2004) Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. *Oncogene* **23**: 2057–2070
- Orth JD, McNiven MA (2007) Get off my back! Rapid receptor internalization through circular dorsal ruffles. *Cancer Res* **66**: 11094–11096
- Tanos B, Pendergast AM (2006) Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. *J Biol Chem* **281**: 32714–32723
- Uramoto H, Mitsudomi T (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? *Br J Cancer* **96**: 857–863